Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Bardales

Cardiovascular Disease Lancaster, OH Medical Doctor

NPI 1619978889 CMS profile 345242

618 Pleasantville Rd, Ste 101, Lancaster, OH 43130

Open in the dashboard

General payments

$7,599

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Bardales of Lancaster, OH is reported in the CMS Open Payments database as having received $7,599 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2023 General $714 30
2022 General $1,989 60
2021 General $1,003 37
2020 General $433 16
2019 General $3,445 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Bardales
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Richard Bardales were reported at $15. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Richard Bardales Cardiovascular Disease median Middle half National median
2019 $3,445 $450 $127–$1,392 $163
2020 $433 $242 $77–$751 $114
2021 $1,003 $335 $101–$1,037 $132
2022 $1,989 $395 $121–$1,211 $149
2023 $714 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $15 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $2,930 20 payments
  2. Medtronic, Inc. $2,081 30 payments
  3. Janssen Pharmaceuticals, Inc $521 26 payments
  4. Novartis Pharmaceuticals Corporation $312 24 payments
  5. Sanofi-Aventis U.S. LLC $249 14 payments
  6. Amgen Inc. $245 15 payments
  7. Pfizer Inc. $132 8 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $115 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $94 5 payments
  10. Amarin Pharma Inc. $88 5 payments
  11. Other $832 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,335 193 payments
  2. Travel and Lodging $2,225 11 payments
  3. Education $39 3 payments
Products named General payments · program years 2019–2025
  1. LINQ II $652 12 payments
  2. XARELTO $521 26 payments
  3. Reveal LINQ Cardiac Diagnostics and Monitoring $441 7 payments
  4. Reveal LINQ Cardiac Diagnostics and Monitoring $254 2 payments
  5. MICRA $253 2 payments
  6. Repatha $245 15 payments
  7. ENTRESTO $218 18 payments
  8. Cobalt $137 2 payments
  9. Crome $130 1 payment
  10. MULTAQ $123 5 payments
  11. Other $2,048 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

98

Median for Internal Medicine: 777

Drug cost

$1,005

Median for Internal Medicine: $73,373

Branded share of claims

17.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 17 $351
Carvedilol Generic 20 $264
Atorvastatin Calcium Generic 12 $156
Amlodipine Besylate Generic 23 $128
Metoprolol Succinate Generic 13 $56
Lisinopril Generic 13 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record